Table 1.
Characteristics of ovarian cancer patients treated with peptide vaccine who were analyzed in this study
| Discovery cohort a | Validation cohort | |
|---|---|---|
| n | 26 | 26 |
| Age, y | ||
| Median (range) | 57.5 (33‐74) | 59 (23‐75) |
| Histology | ||
| Serous adenocarcinoma | 18 | 13 |
| Endometrioid adenocarcinoma | 2 | 5 |
| Mucinous adenocarcinoma | 1 | 1 |
| Clear cell adenocarcinoma | 2 | 2 |
| Others | 3 | 5 |
| Stage | ||
| IIIa | 1 | 0 |
| IIIc | 5 | 2 |
| IV | 1 | 1 |
| Recurrent | 19 | 23 |
| Performance status | ||
| 0 | 23 | 21 |
| 1 | 3 | 5 |
| 2 or more | 0 | 0 |
a
Patients’ data of the discovery cohort have been reported previously.10